BRIEF-Halozyme Reports Proposed Offering Of $500 Mln Of Convertible Senior Notes Due 2027
BRIEF-Halozyme Reports Proposed Offering Of $500 Mln Of Convertible Senior Notes Due 2027
Brief-Halozyme報告提議發售5億美元2027年到期的可轉換優先票據
Feb 23 (Reuters) - Halozyme Therapeutics Inc :
* HALOZYME THERAPEUTICS, INC. ANNOUNCES PROPOSED OFFERING OF $500 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027
* HALOZYME THERAPEUTICS - INTENDS TO OFFER, SUBJECT TO MARKET CONDITIONS AND OTHER FACTORS, $500 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* HALOZYME THERAPEUTICS, INC. ANNOUNCES PROPOSED OFFERING OF $500 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027
* HALOZYME THERAPEUTICS - INTENDS TO OFFER, SUBJECT TO MARKET CONDITIONS AND OTHER FACTORS, $500 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
Feb 23 (Reuters) - Halozyme Therapeutics Inc :
* HALOZYME THERAPEUTICS, INC. ANNOUNCES PROPOSED OFFERING OF $500 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027
* HALOZYME THERAPEUTICS - INTENDS TO OFFER, SUBJECT TO MARKET CONDITIONS AND OTHER FACTORS, $500 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透2月23日電-Halozyme治療公司:*Halozyme治療公司宣佈擬發售5億美元2027年到期的可轉換優先票據*Halozyme Treeutics-打算根據市場狀況和其他因素,發售2027年到期的5億美元可轉換優先票據Eikon的源文本:進一步的公司報道:(Reurs.Briefs@thomsonreurs.com;)
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!